EAM
NUVB icon

Exome Asset Management’s Nuvation Bio NUVB Stock Holding History

Exome Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-96,311
Closed -$170K – 76
2025
Q1 		$170K Buy
+96,311
New +$219K 0.15% 50

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Exome Asset Management's NUVB Position: Q2 2025 in Review

Exome Asset Management sold out of Nuvation Bio (NUVB) in Q2 2025, closing a stake of 96,311 shares — an estimated $170K sold.

Exome Asset Management first reported a position in NUVB in Q1 2025 and held it in 1 quarter. The position peaked at $170K in Q1 2025. 182 funds tracked by Wall St. Rank hold NUVB as of Q2 2025.

  • Exome Asset Management reported no remaining Nuvation Bio position as of Q2 2025 after selling out during the quarter.
  • Exome Asset Management sold 96,311 Nuvation Bio shares in Q2 2025, an estimated $170K.
  • Exome Asset Management first reported a position in Nuvation Bio in Q1 2025 and held it in 1 quarter.
  • Exome Asset Management's Nuvation Bio position peaked at $170K in Q1 2025.
  • 182 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2025.

Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.